|
Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION primary analysis. |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche |
Travel, Accommodations, Expenses - PharmaMar |
|
|
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Merck; Roche/Genentech |
Research Funding - AstraZeneca (Inst); Merck (Inst); Regeneron (Inst); Roche/Genentech (Inst); Tesaro (Inst) |
|
|
Honoraria - Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; mersana; MSD Oncology; Novartis; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro |
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Roche; Sotio |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Immunogen; Mersana; PharmaMar; Roche; Tesaro |
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Clovis Oncology (Inst); Eisai (Inst); Regeneron (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche |
|
|
Speakers' Bureau - AstraZeneca; Roche |
Research Funding - AstraZeneca; Clovis Oncology; Pfizer; Tesaro |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; Genmab; Immunogen; MSD; Oncoinvent; Pfizer/EMD Serono; Roche; Tesaro/GSK |
Speakers' Bureau - AstraZeneca; PharmaMar; Roche; Tesaro/GSK |
Research Funding - Roche (Inst); Tesaro/GSK (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche; Tesaro/GSK |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline |
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Artios; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Merck; Pfizer; Tesaro |
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Pfizer; Tesaro/GSK |
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst) |
Travel, Accommodations, Expenses - Clovis Oncology |
Other Relationship - Regeneron |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
Stock and Other Ownership Interests - AstraZeneca; Pfizer |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
No Relationships to Disclose |